Avastin Gets FDA Approval for New Use
The US Food and Drug Administration (FDA) has approved a new use for the cancer medication Avastin (bevacizumab), according to biotechnology company Genentech.
Using Ovarian Tumor Type to Predict Rx Benefit
Customizing treatments based on a patient’s genetics has led to more effective cancer treatments. Now, researchers have reported using ovarian cancer tumor types to predict how much one medication might benefit patients.
Rx Combo Showed Promise for Ovarian Cancer
Ovarian cancer is the second most common cancer of the female reproductive organs. It's common for this cancer to return after initial treatment, but two therapies used together may help fight this cancer.
UK authority recommends against bevacizumab as advanced ovarian cancer treatment
The National Institute for Health and Clinical Excellence (NICE) has published draft guidance today (18 December) on the use of bevacizumab ( Avastin , Roche) as a treatment for women with advanced ovarian cancer. The draft guidance does not recommend the use of bevacizumab when used with paclitaxel and carboplatin for people with advanced disease, as a cost-effective treatment for the NHS. This draft guidance has now been issued for consultation: NICE has not yet published final guidance to the NHS. The Institute is aware that UK clinical practice is to prescribe bevacizumab at a d...
Roche Drug Receives New European Union Approval
Roche announced that the European Commission has approved Avastin ( bevacizumab ) in combination with standard chemotherapy ( carboplatin and paclitaxel ) as a front-line (first-line following surgery) treatment for women with advanced ovarian cancer.